Dyslipidemia management in diabetes
ConclusionsSeveral existing and newer drug treatments reduce ASCVD risk through LDL cholesterol and/or triglyceride reduction in patients with diabetes. Novel approaches using antisense oligonucleotides and monoclonal antibodies may provide potential future therapies for diabetic dyslipidemia.
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
More News: Canada Health | Cardiology | Cardiovascular | Cholesterol | Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Pancreatitis | Statin Therapy | Vytorin | Zetia